Skip to content
Tuesday, October 27, 2026 · Today’s edition, 6:30 a.m. ETTue, Oct 27 · 6:30 a.m. editionSign inMy Desk 0EditionsSign in

IGSBvsXBI

iShares 1-5 Year Investment Grade Corporate Bond ETF against SPDR S&P Biotech ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IGSB 97XBI 135Oct 25Oct 26GROWTH OF $100
Head to head
IGSBXBI
Expense ratio0.040%0.35%
Assets$23.7B$10.4B
Net flow, 1 month+$51M+$534M
Net flow, 1 year+$2.5B+$1.3B
Return, YTD-2.7%+23.4%
Return, 1 year——
Avg daily volume5.3M9.7M
Holdings3892135
ListedJan 5, 2007Jan 31, 2006
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

ETF Dailyfrom Private Wealth Daily

ETF launches, fund research, and market coverage in your inbox every morning. Free.

Free. Every morning. Unsubscribe from any edition in one click.